Organon & Co.(OGN)Earnings, Financials & Key RatiosOrganon & Co. (OGN) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's high debt-to-EBITDA ratio of 24.41 and persistent revenue contraction suggest significant long-term solvency risks that outweigh the current 2.5% dividend yield.
Organon & Co. (OGN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Organon & Co. (OGN) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $0.71vs $0.83-14.5% | $1.5Bvs $1.5B-1.9% |
| Q1 2026 | Feb 12, 2026 | $0.63vs $0.73-13.7% | $1.5Bvs $1.5B-1.8% |
| Q4 2025 | Nov 10, 2025 | $1.01vs $0.93+8.6% | $1.6Bvs $1.5B+5.3% |
| Q3 2025 | Aug 5, 2025 | $1.00vs $0.94+6.4% | $1.6Bvs $1.6B+2.1% |
Recent stock market news and headlines for Organon & Co. (OGN)
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Are TBRG, OGN, MDV Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 25, 2026
KIRKLAND, Quebec & SHANGHAI--(BUSINESS WIRE)--Organon Canada and Henlius expand access to denosumab treatments with launch of BILDYOS® and TUZEMTY® biosimilars to PROLIA and XGEVA.
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Key metrics vs top competitors for Organon & Co. (OGN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $13.51 | $3.55B | 18.76 | -2.92% | 3.01% | 30.56% | 2.5% | |
| $24.07 | $136.92B | 17.70 | -1.65% | 11.83% | 8.34% | — | |
| $16.96 | $19.75B | -5.65 | -2.98% | -2.04% | -1.97% | — | |
| $254.65 | $449.91B | 107.45 | 8.57% | 5.79% | 67.46% | — | |
| $9.84 | $43.82B | 20.41 | -3.96% | 14.46% | 19.9% | — | |
| $33.44 | $38.94B | 27.87 | 4.31% | 9.02% | 20.69% | — |
Organon & Co. (OGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Organon & Co. (OGN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Apr 30, 2026·SEC
Apr 27, 2026·SEC
Feb 20, 2026·SEC
Get notified when OGN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Organon & Co. (OGN) stock FAQ — growth, dividends, profitability & financials explained
Organon & Co. (OGN) reported $6.16B in revenue for fiscal year 2025. This represents a 37% decrease from $9.78B in 2018.
Organon & Co. (OGN) saw revenue decline by 2.9% over the past year.
Yes, Organon & Co. (OGN) is profitable, generating $246.0M in net income for fiscal year 2025 (3.0% net margin).
Yes, Organon & Co. (OGN) pays a dividend with a yield of 2.50%. This makes it attractive for income-focused investors.
Organon & Co. (OGN) has a return on equity (ROE) of 30.6%. This is excellent, indicating efficient use of shareholder capital.
Organon & Co. (OGN) generated $614.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
